Teva slumps after Express Scripts funds migraine rivals in US

A major prescription benefit manager in the US will not reimburse Teva’s preventative migraine drug Ajovy (fremanezumab), in an effort to cut costs.

However, Express Script Holdings, which is one of the largest pharmacy benefits managers (PBMs) in the US, will cover new migraine drugs produced by competitor pharma firms Eli Lilly and Amgen.